Skip to main content
NCBI home page
Cellular Oncology logoLink to Cellular Oncology
. 2023 Oct 16;46(6):1871–1872. doi: 10.1007/s13402-023-00890-x

Correction: Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity

Yi Yang 1,#, Siqi Wang 2,#, Jiaoyang Cai 2,#, Jianwei Liang 2,#, Yingwen Zhang 1, Yangyang Xie 2, Fei Luo 3, Jingyan Tang 2, Yijin Gao 2,✉, Shuhong Shen 2,✉, Haizhong Feng 3,✉, Yanxin Li 1,✉
PMCID: PMC12974693  PMID: 37843798

Cellular Oncology (2022) 46:133-143

10.1007/s13402-022-00739-9

In Fig. 5f of this article the representative MYCN IHC images of tumor from vehicle-treated mice presented the wrong samples.

Fig. 5.

Fig. 5

Open in a new tab

Targeting ARHGEF12 with the small molecular inhibitor Y16 reduces neuroblastoma tumorigenicity. (f) Representative images of MYCN and Ki-67 staining in tumor sections from d. Scale bar, 50 µm.

The correct Figure 5f is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused.

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s13402-022-00739-9

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yi Yang, Siqi Wang, Jiaoyang Cai, and Jianwei Liang contributed equally to this work.

Contributor Information

Yijin Gao, Email: gaoyijin@scmc.com.cn.

Shuhong Shen, Email: shenshuhong@scmc.com.cn.

Haizhong Feng, Email: fenghaizhong@sjtu.edu.cn.

Yanxin Li, Email: liyanxin@scmc.com.cn.

Articles from Cellular Oncology are provided here courtesy of Springer

RESOURCES